肝内胆管结石合并肝内胆管癌患者癌组织中NOD样受体蛋白3的表达及其与患者术后生存的关系

doi:10.3969/j.issn.1671-7171.2025.02.033

Abstract
Figure/Table
References
Related Citation (15)

[1] 李金海, 朱明辉, 孙丽形, 等. HDGF、VEGF及黏蛋白5B过表达与肝胆管结石相关肝内胆管癌生物学行为及预后的关系[J].中华肝胆外科杂志, 2022, 28(2):6-11.
[2] HAN J Y, AHN K S, BAEK W K, et al. Usefulness of bile as a biomarker via ferroptosis and cysteine prenylation in cholangiocarcinoma; role of diagnosis and differentiation from benign biliary disease[J].Surg Oncol,2020, 34(12):174.
[3] 苏敬博, 张景玮, 陈晨, 等. 辅助化疗对肝内胆管癌根治性切除术后患者预后的影响[J].中华外科杂志, 2022, 60(4):357-363.
[4] CLEMENTS O, ELIAHOO J, KIM J U, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis[J].J Hepatol,2020,72(1):95-103.
[5] HAMARSHEH S, ZEISER R. NLRP3 inflammasome activation in cancer: a double-edged sword[J].Front Immunol,2020, 11:1444.
[6] 王桥, 宋波, 冯博, 等. NOD样受体在口腔鳞状细胞癌中的表达及意义[J].中国老年学杂志, 2021, 41(24):5520-5522.
[7] 唐陈伟, 汤朝晖, 全志伟. 肝内胆管癌的诊断与分类方法[J].中华外科杂志, 2019, 57(4):313-315.
[8] 金星. 肝内胆管结石并胆管癌组织中表皮生长因子受体表达水平及其意义[J].临床合理用药杂志, 2020, 13(6):168.
[9] MEJIA J C, PASKO J. Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma[J].Surg Clin North Am,2020, 100(3):535-549.
[10] 柏杨, 刘洪, 方征,等. 高迁移率族蛋白1在肝内胆管癌中的作用及其与肿瘤微血管形成的关系[J].中国普通外科杂志 2020, 29(2): 171-178.
[11] 林谦益, 简志威, 彭竞源, 等. 临床与病理评估无淋巴结转移的肝内胆管癌患者术后预后对比[J].中国肿瘤临床, 2021, 48(14): 703-710.
[12] JU M Y, BI J, WEI Q, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer[J].Brief Bioinform,2021, 22(4): 38-41.
[13] 刘帆, 韩秀珍, 孙妍. Nod样受体蛋白3炎性小体及细胞焦亡在支气管哮喘中的作用[J].中华实用儿科临床杂志, 2020, 35(12):955-957.
[14] BIASIZZO M, KOPITAR-JERALA N. Interplay between NLRP3 inflammasome and autophagy[J].Front Immunol,2020, 11: 591803.
[15] HUANG Y, XU W, ZHOU R B. NLRP3 inflammasome activation and cell death[J].Cell Mol Immunol,2021, 18(9):2114-2127.